← Back to All US Stocks

UHS Stock Analysis - UNIVERSAL HEALTH SERVICES INC AI Rating

UHS NYSE Services-General Medical & Surgical Hospitals, NEC DE CIK: 0000352915
Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31
AI Rating
BUY
78% Confidence

Investment Thesis

UHS demonstrates solid operational fundamentals with double-digit operating margins (11.5%) and strong profitability metrics (20.5% ROE, 9.6% ROA), supported by consistent revenue growth of 9.7% YoY. The company generates healthy operating and free cash flow (FCF: $849.2M) with adequate interest coverage (12.8x), though tight liquidity (1.05x current ratio) and moderate leverage (0.65x debt/equity) warrant monitoring.

UHS Strengths

  • + Strong profitability with 11.5% operating margin and 8.6% net margin in healthcare services
  • + Excellent return metrics (20.5% ROE, 9.6% ROA) indicate efficient capital utilization
  • + Consistent revenue growth of 9.7% YoY with 37.3% diluted EPS growth
  • + Robust interest coverage ratio of 12.8x demonstrates comfortable debt servicing capacity
  • + Positive free cash flow generation of $849.2M provides financial flexibility

UHS Risks

  • ! Tight liquidity position with current ratio of 1.05x limits operational flexibility for unexpected challenges
  • ! Modest free cash flow margin of 4.9% relative to revenue suggests limited margin for error
  • ! Significant long-term debt of $4.8B requires sustained operational performance and cash generation
  • ! Healthcare sector exposure to regulatory, reimbursement, and labor cost pressures
  • ! Limited cash reserves ($137.8M) relative to total assets suggests reliance on operational cash flow

Key Metrics to Watch

UHS Financial Metrics

Revenue
$17.4B
Net Income
$1.5B
EPS (Diluted)
$23.10
Free Cash Flow
$849.2M
Total Assets
$15.5B
Cash Position
$137.8M

UHS Profitability Ratios

Gross Margin N/A
Operating Margin 11.5%
Net Margin 8.6%
ROE 20.5%
ROA 9.6%
FCF Margin 4.9%

UHS Balance Sheet & Liquidity

Current Ratio
1.05x
Quick Ratio
1.05x
Debt/Equity
0.65x
Debt/Assets
0.0%
Interest Coverage
12.78x
Long-term Debt
$4.8B

UHS 5-Year Financial Trend

UHS 5-year financial data: Year 2021: Revenue $12.6B, Net Income $814.9M, EPS $9.13. Year 2022: Revenue $13.4B, Net Income $944.0M, EPS $10.99. Year 2023: Revenue $14.3B, Net Income $991.6M, EPS $11.82. Year 2024: Revenue $15.8B, Net Income $675.6M, EPS $9.14. Year 2025: Revenue $17.4B, Net Income $717.8M, EPS $10.23.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: UNIVERSAL HEALTH SERVICES INC's revenue has grown significantly by 37% over the 5-year period, indicating strong business expansion. The most recent EPS of $10.23 reflects profitable operations.

UHS Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
4.9%
Free cash flow / Revenue

UHS Quarterly Performance

Quarterly financial performance data for UNIVERSAL HEALTH SERVICES INC including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $4.0B $258.7M $3.80
Q2 2025 $3.9B $289.2M $4.26
Q1 2025 $3.8B $261.8M $3.82
Q3 2024 $3.6B $167.0M $2.40
Q2 2024 $3.5B $171.3M $2.42
Q1 2024 $3.5B $163.1M $2.28
Q3 2023 $3.3B $167.0M $2.40
Q2 2023 $3.3B $164.1M $2.20

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

UHS Capital Allocation

Operating Cash Flow
$1.9B
Cash generated from operations
Stock Buybacks
$968.0M
Shares repurchased (TTM)
Capital Expenditures
$1.0B
Investment in assets
Dividends Paid
$51.3M
Returned to shareholders

UHS SEC Filings

Access official SEC EDGAR filings for UNIVERSAL HEALTH SERVICES INC (CIK: 0000352915)

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31 | Powered by Claude AI